{"log_id": 8049615129985134256, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 0, "average": 0.988608, "min": 0.988608}, "location": {"width": 32, "top": 169, "height": 32, "left": 356}, "words": "险"}, {"probability": {"variance": 0.039253, "average": 0.86755, "min": 0.414719}, "location": {"width": 871, "top": 192, "height": 66, "left": 413}, "words": "大降低色括心血管栓客件在的这些风险,应使用可避免红细胞"}, {"probability": {"variance": 0.012631, "average": 0.877952, "min": 0.71637}, "location": {"width": 166, "top": 274, "height": 34, "left": 358}, "words": "注的最小剂量"}, {"probability": {"variance": 0.01828, "average": 0.927608, "min": 0.536039}, "location": {"width": 489, "top": 315, "height": 50, "left": 416}, "words": "Ess仅用于十骨翻抑制性化疗引起的贫血"}, {"probability": {"variance": 0.017082, "average": 0.951718, "min": 0.496219}, "location": {"width": 567, "top": 365, "height": 54, "left": 416}, "words": "EAa不适用于骨抑制治疗患者贫症状除时"}, {"probability": {"variance": 0.005783, "average": 0.965839, "min": 0.700311}, "location": {"width": 384, "top": 425, "height": 45, "left": 416}, "words": "化疗疗程结束后,应停止使用E"}, {"probability": {"variance": 0.03713, "average": 0.870221, "min": 0.361067}, "location": {"width": 928, "top": 461, "height": 64, "left": 358}, "words": "3文款报道,对手术期未进行预防性抗凝处理患者应压重组人促红素可"}, {"probability": {"variance": 0.036091, "average": 0.868877, "min": 0.409482}, "location": {"width": 745, "top": 518, "height": 61, "left": 365}, "words": "加患者发生深部静脉血栓的几三。应注深部静血的预防"}, {"probability": {"variance": 0.022319, "average": 0.907353, "min": 0.40453}, "location": {"width": 898, "top": 569, "height": 66, "left": 363}, "words": "4、文献报道,对于单纯红细胞再生障性贫血(PRCA3和重症贫血的患者"}, {"probability": {"variance": 0.012708, "average": 0.913821, "min": 0.573942}, "location": {"width": 928, "top": 621, "height": 66, "left": 365}, "words": "半自不伴有其他血细胞减少,有报道伴有促红素中和抗体出现。上述报道主"}, {"probability": {"variance": 0.04238, "average": 0.827853, "min": 0.358533}, "location": {"width": 928, "top": 672, "height": 70, "left": 365}, "words": "见于支下给于ESAs治疗的CRF(慢性肾功能衰游)患若、另有报,BC:也"}, {"probability": {"variance": 0.029564, "average": 0.902314, "min": 0.412516}, "location": {"width": 930, "top": 727, "height": 66, "left": 365}, "words": "见于采用干扰素联合利韦林治疗丙型肝炎过程中给8As的患者。若患者突"}, {"probability": {"variance": 0.026556, "average": 0.911701, "min": 0.382702}, "location": {"width": 930, "top": 779, "height": 66, "left": 365}, "words": "然对态品失去反应,并伴重症食及织红计数降低,应立即评估品失效的"}, {"probability": {"variance": 0.006376, "average": 0.962006, "min": 0.64179}, "location": {"width": 930, "top": 832, "height": 64, "left": 368}, "words": "原因,包括促红素中和抗体的出现,如怀疑为与抗促红紫抗体有关的贫血,则"}, {"probability": {"variance": 0.017677, "average": 0.919898, "min": 0.512839}, "location": {"width": 925, "top": 884, "height": 66, "left": 368}, "words": "应用ESA5,对抗体介异性贫血患者,应永久停用重组人促红素,因为抗体可"}, {"probability": {"variance": 0.036608, "average": 0.89206, "min": 0.381147}, "location": {"width": 525, "top": 948, "height": 52, "left": 370}, "words": "产生交叉反应,也不可用其他ESAs药物"}, {"probability": {"variance": 0, "average": 0.997899, "min": 0.997102}, "location": {"width": 105, "top": 1017, "height": 32, "left": 377}, "words": "一般注意"}, {"probability": {"variance": 0.005093, "average": 0.961078, "min": 0.688026}, "location": {"width": 777, "top": 1044, "height": 64, "left": 370}, "words": "1、生物品的肠外给药,应注意过敏或其它不良反应的发生"}, {"probability": {"variance": 0, "average": 0.998167, "min": 0.998167}, "location": {"width": 27, "top": 1127, "height": 27, "left": 370}, "words": "2"}, {"probability": {"variance": 0.029365, "average": 0.920615, "min": 0.350817}, "location": {"width": 841, "top": 1092, "height": 66, "left": 459}, "words": "品用药期问应定期检查红细胞压积〔用药初期每星期一次,维持期每"}, {"probability": {"variance": 0.017763, "average": 0.911249, "min": 0.497449}, "location": {"width": 930, "top": 1147, "height": 66, "left": 372}, "words": "两星期一次),注意避免过的红细胞成《认红细胞压积36v1以下),如"}, {"probability": {"variance": 0.026368, "average": 0.902862, "min": 0.43112}, "location": {"width": 928, "top": 1198, "height": 70, "left": 377}, "words": "发现过淀的红红胞生长,应采取暂用药等适当处理,用3600/支规格的"}, {"probability": {"variance": 0.017953, "average": 0.945256, "min": 0.380577}, "location": {"width": 925, "top": 1250, "height": 70, "left": 377}, "words": "本品时,还应定检查红蛋白(每1至2个灵期检查一次),当血红蛋白高于"}, {"probability": {"variance": 0.02666, "average": 0.912389, "min": 0.504144}, "location": {"width": 859, "top": 1307, "height": 64, "left": 384}, "words": "20g/1时,不建议继续绐药,如发现过度的红细胞生长,应采瑕适当"}, {"probability": {"variance": 0.031324, "average": 0.877573, "min": 0.429604}, "location": {"width": 848, "top": 1358, "height": 66, "left": 457}, "words": "接受治疗的CRF患者中罕见有血啡房加重。对血啉病患者,应怕用"}, {"probability": {"variance": 0.022473, "average": 0.918302, "min": 0.481141}, "location": {"width": 932, "top": 1408, "height": 70, "left": 379}, "words": "重组人促红紫,治疗期闫,可能发生绝对或功能性缺:功能性缺铁时,铁"}, {"probability": {"variance": 0.029063, "average": 0.881934, "min": 0.394119}, "location": {"width": 930, "top": 1460, "height": 70, "left": 381}, "words": "蛋白水平王常,但转铁蛋白和度降,其原因可能是因为不能迅动员和"}, {"probability": {"variance": 0.025381, "average": 0.909272, "min": 0.406074}, "location": {"width": 930, "top": 1513, "height": 70, "left": 381}, "words": "放内的储存铁以满足促红素刺激作用下肾造血加快对的求,转蛋白"}, {"probability": {"variance": 0.036263, "average": 0.707864, "min": 0.367348}, "location": {"width": 409, "top": 1586, "height": 48, "left": 388}, "words": "200,铁蛋白应10g"}, {"probability": {"variance": 0.03397, "average": 0.873572, "min": 0.448113}, "location": {"width": 450, "top": 1563, "height": 54, "left": 861}, "words": "本治疗首和治疗期间,对老进行"}, {"probability": {"variance": 0.045789, "average": 0.814633, "min": 0.381198}, "location": {"width": 935, "top": 1616, "height": 75, "left": 384}, "words": "状态评估,计估指标包括;转铁蛋白饱和度指血清铁与转铁蛋白结合能刀"}, {"probability": {"variance": 0.028701, "average": 0.865052, "min": 0.411597}, "location": {"width": 932, "top": 1671, "height": 73, "left": 384}, "words": "的比值)和血铁蛋白,生际上所有总者最终都需要铁以提高现维持转铁蛋"}, {"probability": {"variance": 0.00048, "average": 0.981998, "min": 0.9445}, "location": {"width": 96, "top": 1897, "height": 34, "left": 1303}, "words": "华北制药"}, {"probability": {"variance": 1.1e-05, "average": 0.996636, "min": 0.991209}, "location": {"width": 125, "top": 1929, "height": 34, "left": 1300}, "words": "技术份有"}], "language": 3}